| abstract |
The invention relates to a new strain of recombinant modified vaccinia virus Ankara (MVA), used as a vaccine against infections caused by respiratory syncytial virus (RSV virus). In particular, the invention relates to a genetically engineered recombinant MVA, comprising at least one nucleotide sequence encoding an antigenic determinant of the membrane RSV glycoprotein F and at least one nucleotide sequence encoding an RSV M2 matrix protein. The invention also relates to compositions and methods that are suitable for influencing an immune response in a subject or are suitable for diagnosing an RSV infection, as well as for determining whether there is a danger of a relapse of an RSV infection in a subject. |